Pregnenolone sulphate-and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction

Circulation Research

Volumn 106, Issue 9, 2010, Pages 1507-1515

  Naylor, Jacqueline ^a   Li, Jing ^a   Milligan, Carol J ^a   Zeng, Fanning ^a   Sukumar, Piruthivi ^a   Hou, Bing ^a   Sedo, Alicia ^a   Yuldasheva, Nadira ^a   Majeed, Yasser ^a   Beri, Dhananjay ^a   Jiang, Shan ^a   Seymour, Victoria A L ^a   McKeown, Lynn ^a   Kumar, Bhaskar ^a   Harteneck, Christian ^b   O'Regan, David ^c   Wheatcroft, Stephen B ^a   Kearney, Mark T ^a   Jones, Clare ^d   Porter, Karen E ^a   Beech, David J ^a   more..

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Calcium channel; Cholesterol; Interleukin; Neurosteroid; Transient receptor potential; Vascular smooth muscle

Indexed keywords

BETA CYCLODEXTRIN; CALCIUM; CALCIUM CHANNEL L TYPE; CHOLESTEROL; INTERLEUKIN 6; MESSENGER RNA; PREGNENOLONE SULFATE; SPHINGOSINE; TRANSIENT RECEPTOR POTENTIAL CHANNEL M3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; CALCIUM TRANSPORT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; EMBRYO; FEMORAL ARTERY; FOAM CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL LINE; CELL PROLIFERATION; CHOLESTEROL; HUMANS; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PREGNENOLONE; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; TRPM CATION CHANNELS;

EID: 77952426769     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.219329     Document Type: Article

References (34)

1. Flockerzi V. An introduction on TRP channels. Handb Exp Pharmacol. 2007;179:1-19.
2. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev. 2007;87:165-217.
3. Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem. 2007; 76:387-417.
4. Lee N, Chen J, Sun L, Wu S, Gray KR, Rich A, Huang M, Lin JH, Feder JN, Janovitz EB, Levesque PC, Blanar MA. Expression and characterization of human transient receptor potential melastatin 3 (hTRPM3). J Biol Chem. 2003;278:20890-20897.
5. Grimm C, Kraft R, Schultz G, Harteneck C. Activation of the melastatin-related cation channel TRPM3 by D-erythro-sphingosine. Mol Pharmacol. 2005;67:798-805.
6. Oberwinkler J, Lis A, Giehl KM, Flockerzi V, Philipp SE. Alternative splicing switches the divalent cation selectivity of TRPM3 channels. J Biol Chem. 2005;280:22540-22548.
7. Oberwinkler J, Phillipp SE.Trpm3. Handb Exp Pharmacol. 2007;179: 253-267.
8. Grimm C, Kraft R, Sauerbruch S, Schultz G, Harteneck C. Molecular and functional characterization of the melastatin-related cation channel TRPM3. J Biol Chem. 2003;278:21493-21501.
9. Wagner TF, Loch S, Lambert S, Straub I, Mannebach S, Mathar I, Dufer M, Lis A, Flockerzi V, Philipp SE, Oberwinkler J. Transient receptor potential M3 channels are ionotropic steroid receptors in pancreatic beta cells. Nat Cell Biol. 2008;10:1421-1430.
10. Naylor J, Milligan CJ, Zeng F, Jones C, Beech DJ. Production of a specific extracellular inhibitor of TRPM3 channels. Br J Pharmacol. 2008;155:567-573.
11. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678.
12. Kuniba H, Yoshiura KI, Kondoh T, Ohashi H, Kurosawa K, Tonoki H, Nagai T, Okamoto N, Kato M, Fukushima Y, Kaname T, Naritomi K, Matsumoto T, Moriuchi H, Kishino T, Kinoshita A, Miyake N, Matsumoto N, Niikawa N. Molecular karyotyping in 17 patients and mutation screening in 41 patients with Kabuki syndrome. J Hum Genet. 2009;54:304-309.
13. Beech DJ. Emerging functions of 10 types of TRP cationic channel in vascular smooth muscle. Clin Exp Pharmacol Physiol. 2005;32:597-603.
14. Inoue R, Jensen LJ, Shi J, Morita H, Nishida M, Honda A, Ito Y. Transient receptor potential channels in cardiovascular function and disease. Circ Res. 2006;99:119-131.
15. Yang XR, Lin MJ, McIntosh LS, Sham JS. Functional expression of transient receptor potential melastatin-and vanilloid-related channels in pulmonary arterial and aortic smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2006;290:L1267-L1276.
16. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801.
17. Angelini GD, Jeremy JY. Towards the treatment of saphenous vein bypass graft failure-a perspective of the Bristol Heart Institute. Biorheology. 2002; 39:491-499.
18. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol. 2006;59:232-239.
19. Ozaki CK. Cytokines and the early vein graft: strategies to enhance durability. J Vasc Surg. 2007;45:A92-A98.
20. Kumar B, Dreja K, Shah SS, Cheong A, Xu SZ, Sukumar P, Naylor J, Forte A, Cipollaro M, McHugh D, Kingston PA, Heagerty AM, Munsch CM, Bergdahl A, Hultgardh-Nilsson A, Gomez MF, Porter KE, Hellstrand P, Beech DJ. Upregulated TRPC1 channel in vascular injury in vivo and its role in human neointimal hyperplasia. Circ Res. 2006;98:557-563.
21. Beech DJ. Ion channel switching and activation in smooth-muscle cells of occlusive vascular diseases. Biochem Soc Trans. 2007;35:890-894.
22. Xu SZ, Sukumar P, Zeng F, Li J, Jairaman A, English A, Naylor J, Ciurtin C, Majeed Y, Milligan CJ, Bahnasi YM, Al-Shawaf E, Porter KE, Jiang LH, Emery P, Sivaprasadarao A, Beech DJ. TRPC channel activation by extracellular thioredoxin. Nature. 2008;451:69-72.
23. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581.
24. Radaelli A, Loardi C, Cazzaniga M, Balestri G, DeCarlini C, Cerrito MG, Cusa EN, Guerra L, Garducci S, Santo D, Menicanti L, Paolini G, Azzellino A, Lavitrano ML, Mancia G, Ferrari AU. Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination. Arterioscler Thromb Vasc Biol. 2007;27:2750-2755.
25. Mayr M, Zampetaki A, Sidibe A, Mayr U, Yin X, De Souza AI, Chung YL, Madhu B, Quax PH, Hu Y, Griffiths JR, Xu Q. Proteomic and metabolomic analysis of smooth muscle cells derived from the arterial media and adventitial progenitors of apolipoprotein E-deficient mice. Circ Res. 2008;102:1046-1056.
26. Tagawa N, Tamanaka J, Fujinami A, Kobayashi Y, Takano T, Fukata S, Kuma K, Tada H, Amino N. Serum dehydroepiandrosterone, dehydroepi-androsterone sulfate, and pregnenolone sulfate concentrations in patients with hyperthyroidism and hypothyroidism. Clin Chem. 2000;46: 523-528.
27. Suzuki E, Handa K, Toledo MS, Hakomori S. Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert. Proc Natl Acad Sci USA. 2004;101:14788-14793.
28. Mathur S, Constable PD, Eppley RM, Tumbleson ME, Smith GW, Tran-quilli WJ, Morin DE, Haschek WM. Fumonisin B(1) increases serum sphinganine concentration but does not alter serum sphingosine concentration or induce cardiovascular changes in milk-fed calves. Toxicol Sci. 2001;60:379-384.
29. Zidovetzki R, Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta. 2007;1768:1311-1324.
30. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008;9:125-138.
31. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451:904-913
32. Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson KO, Nagendran J, Haromy A, Dyck JR, Michelakis ED. Dehydroepiandros-terone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-/3/NFAT axis. Circ. 2009;120:1231-1240.
33. Ii M, Hoshiga M, Negoro N, Fukui R, Nakakoji T, Kohbayashi E, Shibata N, Furutama D, Ishihara T, Hanafusa T, Losordo DW, Ohsawa N. Adrenal androgen dehydroepiandrosterone sulfate inhibits vascular remodeling following arterial injury. Atherosclerosis. 2009;206:77-85.
34. 2+ entry dependent on TRPC1. Circ Res. 2003;93:839-847.